CHEK2

There are 79 papers on CHEK2 in aging research: 1 trial and 24 observational studies in people, 28 in animals, 16 in cells, 9 reviews. The newest story, Oct 13, 2026: “Blood mutations skew pooled human cancer mutation data”.

Gene

79 papers study it31 findings

HGNCMGINCBI GeneTaxon

6 new papers in 30 daysSee all 79 papers on CHEK2

At a glance

CHEK2 shortens lifespan and promotes senescence in mouse models across independent labs, although a study in telomere-dysfunctional mice finds no clear lifespan effect. One group links CHEK2 predicted loss-of-function variants with higher cancer risk in humans. The National Natural Science Foundation of China funds much of this work; Eli Lilly also provides funding.

31 findings in 19 papers from 2003 to 2026, 4 of them since April 2026

The findings reach people, from one lab or study; independent labs found the same change in mice. 14 independent labs in 8 countries.

“the presence of at least one CHEK2 pLoF variant was associated with increased odds of diagnosis with 14 different cancers (odds ratio [OR] range: 1.34-3.21).”
The pleiotropic landscape of rare variant associations with multiple cancers in large biobanksHGG advances2026doi:10.1016/j.xhgg.2026.100662

1 of its findings points the other way.

Mice: replicated by independent labs. Cells and humans: a single group. Worms or flies: nothing yet.
  • 14 independent labs in 8 countries
  • 1 finding against
  • Funders: National Natural Science Foundation of China and others
  • 5 of 31 findings with company ties
  • Human trial1
  • Humans24
  • Animals28
  • Cells16
  • In silico1

Interventions

1

Exercise

upin mice1

1 study
  1. Exercise increases CHEK2 in mice (immediately after treadmill running (TP1) vs baseline and 1 h post).

    “greater expression of DNA-repair and -response genes (Chk2 and Ku80)”

    Animalsimmediately after treadmill running (TP1) vs baseline and 1 h postcardiac muscle

    Acute exercise activates p38 MAPK and increases the expression of telomere-protective genes in cardiac muscle

    Experimental physiology

More on Exercise

Effects

15

Cellular senescence

upin mice2is required forin human cells1

3 studies
  1. CHEK2 is required for cellular senescence in human cells (PARP inhibitor-induced senescence, independent of p53).

    “the cellular senescence caused by PARPis relies on the Chk2‒p21 pathway but not in a p53-dependent manner”

    CellsPARP inhibitor-induced senescence, independent of p53

    Removing therapy-induced senescent cancer cells targets and potentiates the response of pancreatic cancer cells toward PARP inhibitors as maintenance therapy

    Apoptosis : an international journal on programmed cell death

  2. CHEK2 increases cellular senescence in mice (Bmi1 deficiency; shown by Chk2 knockout).

    “Chk2 knockout rescued these defects by reducing oxidative stress and senescence.”

    AnimalsBmi1 deficiency; shown by Chk2 knockoutbone

    Chk2 deletion rescues bone loss and cellular senescence induced by Bmi1 deficiency via regulation of Cyp1a1

    Journal of orthopaedic translation

  3. CHEK2 increases cellular senescence in mice (shown by deletion in Bmi1-/- mice).

    “Mechanistically, Chk2 deletion suppressed oxidative stress, DNA damage, as well as cell senescence.”

    Animalsshown by deletion in Bmi1-/- micemandible

    Chk2 deletion rescues Bmi1 deficiency-induced mandibular osteoporosis by blocking DNA damage response pathway

    American journal of translational research

More on Cellular senescence

Lifespan

downin mice2no changein mice1

3 studies
  1. CHEK2 shortens lifespan in Pthrp KI mice.

    “The Pthrp KI mice with Chk2 deletion exhibited a longer lifespan, improvement in osteoblastic bone formation and skeletal growth”

    Animalsin Pthrp KI miceskeleton

    DNA damage checkpoint pathway modulates the regulation of skeletal growth and osteoblastic bone formation by parathyroid hormone-related peptide

    International journal of biological sciences

  2. CHEK2 shortens lifespan in Terc-deficient mice, shown by knockout.

    “We show that Chk2 deletion improves Terc-associated phenotypes, including lifespan and age-associated pathologies.”

    Animalsin Terc-deficient mice, shown by knockout

    In vivo role of checkpoint kinase 2 in signaling telomere dysfunction

    Aging cell

  3. CHEK2 showed no clear effect on lifespan in telomere dysfunctional mice.

    “CHK2 deletion did not improve the stem-cell function, organ maintenance and lifespan of telomere dysfunctional mice”

    Animalsin telomere dysfunctional mice

    CHK2-independent induction of telomere dysfunction checkpoints in stem and progenitor cells

    EMBO reports

Oxidative stress and ROS signaling

upin mice2

2 studies
  1. CHEK2 increases oxidative stress and ROS signaling in mice (Bmi1 deficiency; shown by Chk2 knockout).

    “Chk2 knockout downregulated Cyp1a1 and mitigated oxidative stress.”

    AnimalsBmi1 deficiency; shown by Chk2 knockoutbone

    Chk2 deletion rescues bone loss and cellular senescence induced by Bmi1 deficiency via regulation of Cyp1a1

    Journal of orthopaedic translation

  2. CHEK2 increases oxidative stress and ROS signaling in mice (shown by deletion in Bmi1-/- mice).

    “Mechanistically, Chk2 deletion suppressed oxidative stress, DNA damage, as well as cell senescence.”

    Animalsshown by deletion in Bmi1-/- micemandible

    Chk2 deletion rescues Bmi1 deficiency-induced mandibular osteoporosis by blocking DNA damage response pathway

    American journal of translational research

More on Oxidative stress and ROS signaling

USP37

upin human cells1

1 study
  1. CHEK2 activates USP37 in human cells (phosphorylates at Thr589).

    “activates CHK2, which phosphorylates USP37 at Thr589, thereby enhancing its binding to FOXO4.”

    Cellsphosphorylates at Thr589

    CHK2-USP37 axis stabilizes FOXO4 to sustain senescence and evade apoptosis

    Proceedings of the National Academy of Sciences of the United States of America

More on USP37

Chemotherapy resistance

downin cells1

1 study
  1. CHEK2 decreases chemotherapy resistance in cells (shown by CHEK2 loss).

    “loss of CHEK2 confers resistance to chemotherapy in hematopoietic stem and progenitor cells (HSPCs).”

    Cellsshown by CHEK2 losshematopoietic stem and progenitor cells

    CHEK2 loss endows chemotherapy resistance to hematopoietic stem cells

    Leukemia

Stem cell maintenance

downin mice1

1 study
  1. CHEK2 decreases stem cell maintenance in mice (shown by deletion in Bmi1-/- mice).

    “In addition, it boosted proliferation of bone marrow mesenchymal stem cells (BM-MSCs) that derived from mandible through blocking the DNA damage response pathway.”

    Animalsshown by deletion in Bmi1-/- micemandible

    Chk2 deletion rescues Bmi1 deficiency-induced mandibular osteoporosis by blocking DNA damage response pathway

    American journal of translational research

More on Stem cell maintenance

Osteoporosis

upin mice1

1 study
  1. CHEK2 increases osteoporosis in mice (shown by deletion in Bmi1-/- mice).

    “Chk2 deletion rescued mandibular osteoporosis through promoting formation of osteoblastic bone as well as decreasing osteoclastic bone resorption.”

    Animalsshown by deletion in Bmi1-/- micemandible

    Chk2 deletion rescues Bmi1 deficiency-induced mandibular osteoporosis by blocking DNA damage response pathway

    American journal of translational research

More on Osteoporosis

Skeletal growth

downin mice1

1 study
  1. CHEK2 impairs skeletal growth in Pthrp KI mice.

    “Chk2 deletion in Pthrp KI mice can somewhat rescue defects in osteoblastic bone formation and skeletal growth by enhancing endochondral bone formation and osteogenesis.”

    Animalsin Pthrp KI miceskeleton

    DNA damage checkpoint pathway modulates the regulation of skeletal growth and osteoblastic bone formation by parathyroid hormone-related peptide

    International journal of biological sciences

Osteoblastic bone formation

downin mice1

1 study
  1. CHEK2 impairs osteoblastic bone formation in Pthrp KI mice.

    “The Pthrp KI mice with Chk2 deletion exhibited a longer lifespan, improvement in osteoblastic bone formation and skeletal growth”

    Animalsin Pthrp KI micebone

    DNA damage checkpoint pathway modulates the regulation of skeletal growth and osteoblastic bone formation by parathyroid hormone-related peptide

    International journal of biological sciences

Colorectal, breast, ovarian and prostate cancer risk

no changein humans1

1 study
  1. CHEK2 was not clearly linked with colorectal, breast, ovarian and prostate cancer risk in humans (CHEK2 del5395 carriers in the Latvian population) (No statistically significant associations; p = 0.39–1.00 across groups).

    “does not have a direct impact on genetic predisposition toward colorectal, breast, ovarian and prostate cancer.”

    HumansCHEK2 del5395 carriers in the Latvian population

    The CHEK2 del5395 is a founder mutation without direct effects for cancer risk in the latvian population

    Balkan journal of medical genetics : BJMG

More on Colorectal, breast, ovarian and prostate cancer risk

All 15

Upstream

3

Ovarian aging

upin mice1

1 study
  1. Ovarian aging increases CHEK2 in mice (aged mice and human ovarian somatic cells).

    “CHK2 and DNA damage markers were increased in aged mice and human ovarian somatic cells.”

    Animalsaged mice and human ovarian somatic cells

    Inhibiting CHK2 improves oocyte quality and reduces ovarian inflammation in aged mice

    bioRxivPreprint

TERF2

downin human cells1

1 study
  1. TERF2 inhibits CHEK2 in cultured EPCs (completely suppressed).

    “Conversely, statin cotreatment or overexpression of TRF2 completely suppressed Chk2 induction.”

    Cellsin cultured EPCs

    Statins enhance migratory capacity by upregulation of the telomere repeat-binding factor TRF2 in endothelial progenitor cells

    Circulation

More on TERF2

Cellular senescence

upin human cells1

1 study
  1. Cellular senescence activates CHEK2 in senescent cells.

    “senescent cells contain activated forms of the DNA damage checkpoint kinases CHK1 and CHK2.”

    Cellsin senescent cells

    A DNA damage checkpoint response in telomere-initiated senescence

    Nature

More on Cellular senescence

Associations

7

Cancer risk

upin humans1

1 study
  1. CHEK2 is linked with a higher risk of cancer risk in humans (presence of at least one CHEK2 pLoF variant) (OR range: 1.34-3.21).

    “the presence of at least one CHEK2 pLoF variant was associated with increased odds of diagnosis with 14 different cancers (odds ratio [OR] range: 1.34-3.21).”

    Humanspresence of at least one CHEK2 pLoF variant

    The pleiotropic landscape of rare variant associations with multiple cancers in large biobanks

    HGG advances

More on Cancer risk

Cellular senescence

upin human cells1

1 study
  1. CHEK2 is associated with cellular senescence in human cells.

    “only CHEK2 showed IPF-specific differential expression and was closely associated with AEC senescence and fibrotic progression”

    Cellsalveolar epithelial cells

    Identification of senescence-related genes in diagnosing idiopathic pulmonary fibrosis via integrating bioinformatics analysis and machine learning

    PloS one

More on Cellular senescence

Idiopathic pulmonary fibrosis

upin humans1

1 study
  1. CHEK2 is associated with idiopathic pulmonary fibrosis in humans.

    “Two senescence-associated hub genes, CHEK2 and TP53 BP1, were identified as key contributors to IPF pathology (FDR-adjusted P < 0.05)”

    Humans

    Identification of senescence-related genes in diagnosing idiopathic pulmonary fibrosis via integrating bioinformatics analysis and machine learning

    PloS one

More on Idiopathic pulmonary fibrosis

Older age group

upin humans1

1 study
  1. CHEK2 is associated with older age group in humans (germline mutation).

    “whereas germline checkpoint kinase 2 (gCHEK2) mutations are more common in elderly patients.”

    Humansgermline mutationfemales

    Age-related genomic characterization and therapeutic targets in Chinese breast cancer: insights from prospective targeted sequencing and clinical data analysis

    BMC medicine

Recurring founder variant in Israel

upin humans1

1 study
  1. CHEK2 is associated with recurring founder variant in Israel in humans (c.592+3A>T variant; PMS2 (c.943C>T) and CDKN2A (c.176T>G) variants reported alongside).

    “CHEK2 (c.592+3A>T), PMS2 (c.943C>T), and CDKN2A (c.176T>G) were identified as potentially recurring founder variants.”

    Humansc.592+3A>T variant; PMS2 (c.943C>T) and CDKN2A (c.176T>G) variants reported alongsiden = 2,990

    Outcomes of multigene panel testing for hereditary cancer in two Israeli medical centers 2013-2024

    Cancer genetics

Age at natural menopause

upin humans1

1 study
  1. CHEK2 is associated with age at natural menopause in humans (CHEK2 c.1100delC heterozygotes compared with non-carriers) (1.5–2.2 years later natural menopause).

    “CHEK2 c.1100delC is associated with 1.5-2.2 years later ANM compared with non-carriers”

    HumansCHEK2 c.1100delC heterozygotes compared with non-carriersfemales

    Later age of natural menopause among women with the pathogenic CHEK2 c.1100delC variant: a validation study

    Journal of medical genetics

Breast cancer

upin humans1

1 study
  1. CHEK2 predicts breast cancer in humans (CHEK2 pathogenic variant carriers) (>20% lifetime risk).

    “Overall, women with CHEK2 PVs had >20% lifetime risk of breast cancer.”

    HumansCHEK2 pathogenic variant carrierslifetimefemales

    Development of a Breast Cancer Risk Prediction Model Integrating Monogenic, Polygenic, and Epidemiologic Risk

    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

More on Breast cancer

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    CHEK2 is associated with senescence in human alveolar epithelial cells and idiopathic pulmonary fibrosis in silico. A preprint reports increased CHEK2 with ovarian aging in mice and human ovarian somatic cells; a human study links CHEK2 pLoF variants to increased cancer risk. Three independent labs report distinct findings, without replication of the same change.

  2. Summary written from the findings.

Latest

Dec 2025: 1Jan 2026: 5Feb 2026: 4Mar 2026: 3Apr 2026: 1May 2026: 2Jun 2026: 1Jul 2026: 3Aug 2026: 3Sep 2026: 2Oct 2026: 7Nov 2026: 133 papers in 12 months
medRxiv

Blood mutations skew pooled human cancer mutation data

For one gene involved in DNA modification, 52.8% of patients flagged as carrying a mutation had no tumor-derived mutation in that gene.For one gene involved in DNA modification, 52.8% of patients flagged as carrying a mutation had no tumor-derived mutation in that gene.

Preprint: computational studyMechanisms

See all 79 papers on CHEK2